Standigm is an AI-driven drug discovery company. Applying its own innovative AI to the real world, Standigm currently has more than 20 preclinical pipelines across various therapeutic areas. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactoryâ„¢, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASKâ„¢ for target discovery, Standigm BESTâ„¢ for lead selection, and Standigm Insightâ„¢ for drug repurposing. Founded in 2015, Standigm has raised $23M from leading investors and developed an elite team with multi-disciplinary expertise in chemistry, biology, pharmacology, artificial intelligence, and data structures to ease the pains of patients all over the world.